# Selepressin Evaluation Programme for Sepsis-Induced Shock - Adaptive Clinical Trial

> **NCT02508649** · PHASE2,PHASE3 · TERMINATED · sponsor: **Ferring Pharmaceuticals** · enrollment: 868 (actual)

## Conditions studied

- Septic Shock

## Interventions

- **DRUG:** selepressin
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02508649
- **Lead sponsor:** Ferring Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-07
- **Primary completion:** 2017-10-03
- **Final completion:** 2018-02-26
- **Target enrollment:** 868 (ACTUAL)
- **Why stopped:** Terminated due to futility
- **Last updated:** 2021-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02508649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02508649, "Selepressin Evaluation Programme for Sepsis-Induced Shock - Adaptive Clinical Trial". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02508649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*